(keyword): FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV

The U.S. Food and Drug Administration has approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for the prevention of certain diseases caused by nine types of Human Papillomavirus (HPV[1]). Covering nine HPV types, five more HPV types than Gardasil (previously approved by the FDA), Gardasil 9 has the potential to prevent approximately 90 percent of cervical, vulvar, vaginal and anal cancers[2]. Gardasil 9 is a vaccine approved for use in […]

breast: Rutgers Cancer Institute of New Jersey aids in clinical trial examining effects of ‘chemo brain’ in breast cancer patients

Rutgers Cancer Institute of New Jersey is referring breast cancer[1] patients to a clinical trial examining the side effects of chemotherapy[2] and hormonal therapy on the brain. When receiving treatment for breast cancer, patients sometimes experience side effects that can make it harder for them to concentrate, remember things or do tasks requiring rapid or precise hand movements. Referred to as “chemo brain,” these changes can affect a patient’s quality […]

cervical: Trust in cervical cancer screening is strong – extending time between tests triggers concern

A newly released survey, Cervical Cancer Today: A National Survey of Attitudes and Behaviors, paints a picture of women and their healthcare providers as resistant to changes in one of the most successful cancer[1] prevention programs in U.S. history: cervical cancer[2] screening. The survey, conducted jointly by the National Association of Nurse Practitioners in Women’s Health (NPWH) and HealthyWomen (HW), explored the attitudes and decisions in the exam room of […]


breast: Lung cancer to overtake breast cancer as most fatal among European women

According to the latest predictions – published in the Annals of Oncology – lung cancer death rates will outnumber breast cancer death rates among European women in 2015 for the first time. The study claims that the overall death rate for lung cancer among women in Europe is driven by rates in the UK and Poland. The authors of the new study say that although the number of deaths from […]

lung: FDA expands approved use of Cyramza to treat aggressive non-small cell lung cancer (NSCLC)

The U.S. Food and Drug Administration has expanded the approved use of Cyramza (ramucirumab) to treat patients with metastatic non-small cell lung cancer[1] (NSCLC). The most common type of lung cancer, NSCLC occurs when cancer[2] cells form in the tissues of the lung. The National Cancer Institute estimates that 224,210 Americans will be diagnosed and 159,260 will die from lung cancer in 2014. Cyramza works by blocking the blood supply […]